Detalles de la búsqueda
1.
Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.
Clin Infect Dis
; 67(suppl_3): S349-S358, 2018 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-30496464
2.
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Antimicrob Agents Chemother
; 59(1): 38-45, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25313213
3.
Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.
Antimicrob Agents Chemother
; 58(1): 503-10, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24189253
4.
Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV.
Antimicrob Agents Chemother
; 58(6): 3468-74, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24709267
5.
The pyrazinamide susceptibility breakpoint above which combination therapy fails.
J Antimicrob Chemother
; 69(9): 2420-5, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24821594
6.
Population pharmacokinetics and pharmacodynamics of nasal glucagon in patients with type 1 or 2 diabetes.
CPT Pharmacometrics Syst Pharmacol
; 2024 May 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38736200
7.
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture.
Antimicrob Agents Chemother
; 57(2): 789-95, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23183433
8.
Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation.
Paediatr Drugs
; 25(3): 377-387, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36973474
9.
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
Lancet Diabetes Endocrinol
; 11(3): 158-168, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36758572
10.
Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease.
Alzheimers Dement (N Y)
; 9(2): e12404, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37388759
11.
Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial.
Diabetes Care
; 46(5): 1060-1067, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36944059
12.
Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes.
Diabetes Care
; 46(5): 1052-1059, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36920867
13.
Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis.
Antimicrob Agents Chemother
; 56(7): 3857-63, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22564839
14.
PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together.
CPT Pharmacometrics Syst Pharmacol
; 11(6): 721-730, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35289125
15.
A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti-SARS-CoV-2 Monoclonal Antibodies to Advance Bamlanivimab Into a First-in-Human Clinical Trial.
Clin Pharmacol Ther
; 111(3): 595-604, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34687040
16.
The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.
Antimicrob Agents Chemother
; 55(9): 4122-7, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21709081
17.
Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID-19 Infection.
Clin Pharmacol Ther
; 110(5): 1302-1310, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34514598
18.
First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19.
Clin Pharmacol Ther
; 110(6): 1467-1477, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34455583
19.
Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics.
CPT Pharmacometrics Syst Pharmacol
; 9(9): 523-533, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32683787
20.
Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia.
Clin Pharmacokinet
; 57(2): 243-254, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28578536